Civica Rx, the nonprofit generic drug company formed by several major health systems, will have eight critical injectable medicines available for its member hospitals by year-end.
The injectables, many of which are in shortage, were manufactured by Hikma Pharmaceuticals.
The medications that will be available to Civica's member hospitals include:
- Heparin, an anticoagulant that has been in shortage
- Naloxone hydrochloride injection, an opioid antagonist
- Dexamethasone sodium phosphate injection, a steroid used to treat allergic reactions, blood diseases, certain cancers, among other conditions
- Glycopyrrolate injection, used in surgeries to reduce airway secretions or prevent heart rhythm problems during surgery
- Prochlorperazine edisylate injection, used to control severe nausea and vomiting
- Ondansetron injection, also used to prevent nausea and vomiting
- Morphine sulfate injection, a narcotic used to treat moderate to severe pain
- Metoprolol tartrate, a beta-blocker used to treat angina and hypertension.
"We are thrilled to be delivering on our partnership’s promise to ensure vital medications are consistently available for hospitals and patients who need them," said Martin VanTrieste, president and CEO of Civica Rx. "These shipments reinforce our confidence in Hikma’s expertise and manufacturing capabilities, and it’s especially gratifying that the initial deliverable of our partnership will help ensure an increased supply of heparin at a time when there is an ongoing threat to supply."
More articles on pharmacy:
UnitedHealth to acquire struggling specialty pharmacy
Pharmaceutical layoffs up nearly 6% from last year
Larger chunk of hospital drug spending going toward cancer treatments, study finds